Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared

Health Policy

Volumn 76, Issue 2, 2006, Pages 134-143

  Cairns, John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cost effectiveness advice; Health technology appraisal

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; EVALUATION; HEALTH CARE ORGANIZATION; HUMAN; MEDICINE; NATIONAL HEALTH SERVICE; REVIEW; UNITED KINGDOM;

EID: 33644696932     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2005.05.006     Document Type: Article

References (12)

1. R.S. Taylor, M.F. Drummond, G. Salkeld, and S.D. Sullivan Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle British Medical Journal 329 2004 972 975
2. National Institute for Clinical Excellence Guide to the methods of technology appraisal 2004 NICE London
3. Scottish Executive Health Department NHS HDL 60 2003 Scottish Executive Edinburgh
4. Scottish Medicines Consortium Annual report 2002-2003 2003 SMC Glasgow
5. National Institute for Clinical Excellence Guide to the technology appraisal process 2004 NICE London
6. N. Devlin, and D. Parkin Does NICE have a cost-effectiveness threshold and what other factors influence its decision? A binary choice analysis Health Economy 13 2004 437 452
7. S. Birch, and A. Gafni The 'NICE' approach to technology assessment: an economics perspective Health Care Management Science 7 2004 35 41
8. Department of Health Implementation of NICE guidance 2004 Department of Health London
9. T.A. Sheldon, N. Cullum, D. Dawson, A. Lankshear, K. Lowson, and I. Watt What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews British Medicine Journal 329 2004 999
10. C. Black Impact evaluation report 2003 Scottish Medicines Consortium & University of Aberdeen Aberdeen
11. House of Commons Health Committee. The influence of the pharmaceutical industry. Fourth Report of session 2004-2005, HC42-1, London: The stationery office; 5 April, 2005.
12. L. Gulácsi, I. Boncz, and M. Drummond Issues for countries considering introducing the "fourth hurdle": the case of Hungary International Journal of Technology Assessment in Health Care 20 2004 337 341